NEW YORK (AP) — Juno Therapeutics and its CEO, Hans E. Bishop, are being named in a lawsuit over whether the biotechnology company misled investors about the death of a patient in a key study involving its drug intended to treat leukemia.
The lawsuit arrives just as the company gained permission by the Food and Drug Administration to restart its study for the leukemia drug candidate.
Bishop was chief operating officer of Dendreon in 2011 when he and other executives at that company were accused of selling shares of stock while misleading investors about the sales outlook for the prostate cancer drug Provenge.
